NCT04899882

Brief Summary

This study aimed to investigate the impact of Physical therapy in adult patients receiving intensive induction chemotherapy for the treatment of acute leukemia during prolonged hospitalization. The study cohort included 150 patients. Primary objective is to compare the effect of a standardized rehabilitation program on physical deconditioning. This study has several secondary objectives of comparing and analyzing the status of sarcopenia, muscle strength, physical performance and the psychic dimension of this intervention. The 6 minutes walking test, Handgrip strength, impedance measurement, computed tomography, Short Physical Performance were used as measures of physical function. Hospital Anxiety and Depression Scale and European Organization for the Research and Treatment of Cancer-Quality of Life-Questionnaire-30 (EORTC-QLQ-30) were used as measures of depression and anxiety and quality of life of cancer patients. To investigate the impact of physical therapy, patients were assigned to the physical therapy group (experimental group) or the control group.These results will thus make it possible to promote access to physiotherapy and rehabilitation care, from diagnosis and during hospitalization, and to standardize practices.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
150

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jan 2022

Typical duration for not_applicable

Geographic Reach
1 country

4 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 19, 2021

Completed
6 days until next milestone

First Posted

Study publicly available on registry

May 25, 2021

Completed
8 months until next milestone

Study Start

First participant enrolled

January 5, 2022

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 5, 2025

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 5, 2025

Completed
Last Updated

November 7, 2022

Status Verified

November 1, 2022

Enrollment Period

3 years

First QC Date

May 19, 2021

Last Update Submit

November 2, 2022

Conditions

Keywords

sarcopeniaexercisecancer related fatigue

Outcome Measures

Primary Outcomes (1)

  • The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity between V1 and V0

    The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes.

    The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity between V1 and V0

Secondary Outcomes (6)

  • The physical performance assessed with Evolution of Short Physical Performance Battery

    The worsening rate of sarcopenia defined either by the occurrence of a status of sarcopenia regardless of the stage or by moving from one sarcopenia stage's to another, 4 to 6 week after hospitalization

  • The muscle mass assessed with Bioelectrical impedance analysis

    The worsening rate of sarcopenia defined either by the occurrence of a status of sarcopenia regardless of the stage or by moving from one sarcopenia stage's to another, 4 to 6 week after hospitalization

  • Anxiety and Depressive Disorders assessed with the Hospital Anxiety and Depression Scale

    Hospital Anxiety and Depression Scale and European Organization for the Research

  • Evolution of activities of daily living assessed with Treatment of Cancer-Quality of Life Questionnaire-30

    The comparison visit 0 versus Visit 1 bis 10 to 15 days after discharge from hospital for induction

  • muscle strength assessed with dynamometer and standing up test chair

    The worsening rate of sarcopenia defined either by the occurrence of a status of sarcopenia regardless of the stage or by moving from one sarcopenia stage's to another, 4 to 6 week after hospitalization

  • +1 more secondary outcomes

Study Arms (2)

Control group

NO INTERVENTION

KinHémo group

EXPERIMENTAL
Other: KinHémo

Interventions

Evaluation and cardiovascular training, combination of resistance and flexibility training

KinHémo group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult patient \>18 years
  • Patient with acute leukemia eligible to receive intensive chemotherapy (induction phase) with predictable deep bone marrow aplasia (polynuclear neutrophils \<500mm3 for more than 8 days) requiring prolonged hospitalization with room confinement.
  • Patient having signed the informed consent to participate in the study

You may not qualify if:

  • Patient with disabilities or contraindications (significant cognitive or psychiatric disorders, significant cardiac or pulmonary pathology, neurological, joint, orthopedic or medical condition, etc.) following an exercise therapy program and carrying out follow-up defined by the protocol and in particular the physical performance tests.
  • Active bleeding, acute thrombosis, ischemia, hemodynamic instability or uncontrolled pain
  • No understanding of the French language
  • Pregnant women, parturients and nursing mothers
  • Persons deprived of their liberty by judicial or administrative decision
  • People under duress psychiatric care
  • Persons subject to legal protection
  • Persons unable to express their consent
  • Person not affiliated to a health insurance scheme or not beneficiary of a social security scheme.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

CHU Angers

Angers, 49933, France

RECRUITING

CHU Brest

Brest, France

RECRUITING

CHU Nantes

Nantes, France

RECRUITING

CHU Tours

Tours, France

RECRUITING

MeSH Terms

Conditions

SarcopeniaMotor Activity

Condition Hierarchy (Ancestors)

Muscular AtrophyNeuromuscular ManifestationsNeurologic ManifestationsNervous System DiseasesAtrophyPathological Conditions, AnatomicalPathological Conditions, Signs and SymptomsSigns and SymptomsBehavior

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 19, 2021

First Posted

May 25, 2021

Study Start

January 5, 2022

Primary Completion

January 5, 2025

Study Completion

March 5, 2025

Last Updated

November 7, 2022

Record last verified: 2022-11

Locations